RU2006120491A - Комбинация для лечения пролиферативных заболеваний - Google Patents
Комбинация для лечения пролиферативных заболеваний Download PDFInfo
- Publication number
- RU2006120491A RU2006120491A RU2006120491/15A RU2006120491A RU2006120491A RU 2006120491 A RU2006120491 A RU 2006120491A RU 2006120491/15 A RU2006120491/15 A RU 2006120491/15A RU 2006120491 A RU2006120491 A RU 2006120491A RU 2006120491 A RU2006120491 A RU 2006120491A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- protein tyrosine
- tyrosine phosphatase
- mitotic kinesin
- reduces
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 230000002062 proliferating effect Effects 0.000 title claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 27
- 230000000394 mitotic effect Effects 0.000 claims 17
- 102000010638 Kinesin Human genes 0.000 claims 15
- 108010063296 Kinesin Proteins 0.000 claims 15
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 claims 14
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 claims 14
- 230000004071 biological effect Effects 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- HXNBAOLVPAWYLT-NVNXTCNLSA-N (5z)-5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound S\1C(=S)NC(=O)C/1=C/C1=CC(Br)=CC=C1OCC1=CC=CC=C1Br HXNBAOLVPAWYLT-NVNXTCNLSA-N 0.000 claims 2
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 2
- 101100522280 Dictyostelium discoideum ptpA1-2 gene Proteins 0.000 claims 2
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 claims 2
- 101710132784 Dual specificity protein phosphatase 1 Proteins 0.000 claims 2
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims 2
- 101710132801 Dual specificity protein phosphatase 4 Proteins 0.000 claims 2
- 102100025734 Dual specificity protein phosphatase CDC14A Human genes 0.000 claims 2
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000932600 Homo sapiens Dual specificity protein phosphatase CDC14A Proteins 0.000 claims 2
- 101000624625 Homo sapiens M-phase inducer phosphatase 1 Proteins 0.000 claims 2
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 claims 2
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 claims 2
- 229940124179 Kinesin inhibitor Drugs 0.000 claims 2
- 102100023326 M-phase inducer phosphatase 1 Human genes 0.000 claims 2
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 claims 2
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101150006497 PTP-1 gene Proteins 0.000 claims 2
- 102100024599 Protein tyrosine phosphatase type IVA 1 Human genes 0.000 claims 2
- 101710138644 Protein tyrosine phosphatase type IVA 1 Proteins 0.000 claims 2
- 102100024602 Protein tyrosine phosphatase type IVA 2 Human genes 0.000 claims 2
- 101710138646 Protein tyrosine phosphatase type IVA 2 Proteins 0.000 claims 2
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 claims 2
- 101710138647 Protein tyrosine phosphatase type IVA 3 Proteins 0.000 claims 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 2
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 2
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 2
- 229940126731 protein tyrosine phosphatase inhibitor Drugs 0.000 claims 2
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000001256 adenosarcoma Diseases 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000000860 cochlear nerve Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000037023 motor activity Effects 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 1
- 201000007321 sebaceous carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51955103P | 2003-11-12 | 2003-11-12 | |
| US60/519,551 | 2003-11-12 | ||
| US10/855,130 | 2004-05-27 | ||
| US10/855,130 US20050100508A1 (en) | 2003-11-12 | 2004-05-27 | Methods for identifying drug combinations for the treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006120491A true RU2006120491A (ru) | 2007-12-20 |
Family
ID=34556562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006120491/15A RU2006120491A (ru) | 2003-11-12 | 2004-11-09 | Комбинация для лечения пролиферативных заболеваний |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1689352A2 (es) |
| JP (1) | JP2007524657A (es) |
| KR (1) | KR20060118514A (es) |
| AR (1) | AR046841A1 (es) |
| AU (1) | AU2004289311A1 (es) |
| BR (1) | BRPI0416390A (es) |
| CA (1) | CA2545423A1 (es) |
| IL (1) | IL175611A0 (es) |
| IS (1) | IS8496A (es) |
| NO (1) | NO20062358L (es) |
| RU (1) | RU2006120491A (es) |
| TW (1) | TW200526777A (es) |
| WO (1) | WO2005046607A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009225877B2 (en) * | 2008-03-18 | 2014-11-20 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
-
2004
- 2004-11-05 TW TW093133826A patent/TW200526777A/zh unknown
- 2004-11-09 WO PCT/US2004/037527 patent/WO2005046607A2/en not_active Ceased
- 2004-11-09 BR BRPI0416390-7A patent/BRPI0416390A/pt not_active Application Discontinuation
- 2004-11-09 KR KR1020067010335A patent/KR20060118514A/ko not_active Withdrawn
- 2004-11-09 EP EP04810676A patent/EP1689352A2/en not_active Withdrawn
- 2004-11-09 RU RU2006120491/15A patent/RU2006120491A/ru not_active Application Discontinuation
- 2004-11-09 AU AU2004289311A patent/AU2004289311A1/en not_active Abandoned
- 2004-11-09 CA CA002545423A patent/CA2545423A1/en not_active Abandoned
- 2004-11-09 JP JP2006539813A patent/JP2007524657A/ja active Pending
- 2004-11-12 AR ARP040104188A patent/AR046841A1/es unknown
-
2006
- 2006-05-11 IL IL175611A patent/IL175611A0/en unknown
- 2006-05-23 NO NO20062358A patent/NO20062358L/no not_active Application Discontinuation
- 2006-06-02 IS IS8496A patent/IS8496A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004289311A1 (en) | 2005-05-26 |
| EP1689352A2 (en) | 2006-08-16 |
| BRPI0416390A (pt) | 2007-02-21 |
| AR046841A1 (es) | 2005-12-28 |
| NO20062358L (no) | 2006-07-12 |
| IS8496A (is) | 2006-06-02 |
| KR20060118514A (ko) | 2006-11-23 |
| CA2545423A1 (en) | 2005-05-26 |
| WO2005046607A3 (en) | 2012-12-20 |
| IL175611A0 (en) | 2008-04-13 |
| WO2005046607A2 (en) | 2005-05-26 |
| TW200526777A (en) | 2005-08-16 |
| JP2007524657A (ja) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brydøy et al. | Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors | |
| Merchant et al. | Prevention and management of lymphedema after breast cancer treatment | |
| Ansaloni et al. | Guidelines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society | |
| Newman | Breast cancer in African‐American women | |
| Stone et al. | Management of oral mucositis in patients with cancer | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| WO2004089416A3 (en) | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent | |
| Kirby et al. | Overactive bladder: is there a link to the metabolic syndrome in men? | |
| MX2007004001A (es) | Metodo para el tratamiento de poliquistosis renal. | |
| Appel et al. | The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain | |
| Schwab et al. | What’s new in primary bone tumors | |
| Zagouri et al. | Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? | |
| WO2006036770A3 (en) | Combination therapy for the treatment of obesity | |
| RU2006120491A (ru) | Комбинация для лечения пролиферативных заболеваний | |
| DE60309887D1 (de) | Kombination von einem aromatasehemmer mit einem bisphosphonat | |
| BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| DE60224299D1 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| Schwab et al. | A window‐of‐opportunity biomarker study of etodolac in resectable breast cancer | |
| He et al. | Priapism as the initial manifestation of a penile and lower limb cutaneous metastasis of prostate adenocarcinoma with low serum PSA level | |
| WO2004070008A8 (en) | Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors | |
| Boccardo et al. | Surgical prevention of Lymphedema following lymph node dissection: LY. MPHA technique. | |
| Hoehne et al. | An update on prognosis in breast cancer patients with extensive axillary disease | |
| Levy et al. | CML-282 Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment | |
| Hodgson et al. | An update on localised prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20071210 |